Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MEDTOX Scientific Reports 2008 Results
For the fourth quarter period, revenues were $20.8 million, against $19.7 million from the prior-year period. The company recorded operating income of $1.1 million for the three-month period,
For the fourth quarter period, revenues were $20.8 million, against $19.7 million from the prior-year period. The company recorded operating income of $1.1 million for the three-month period,
GAAP net income rose to $86.7 million, or $0.31 per diluted share, compared with $78.9 million, or $0.29 per diluted share, in the prior fourth quarter. Non-GAAP net
This products suite includes MammaPrint, the only FDA approved test for rapidly and accurately diagnosing therapeutic options for breast cancer patients. Additionally, he will play an important role
“This past year was pivotal for Sequenom as we continued to advance our genetic analysis and molecular diagnostics businesses,” stated Harry Stylli, president and chief executive officer of
As a result of the court’s decision, Par will accrue additional reserves of approximately $28 million on an after-tax basis in the fourth quarter of 2008. Par and
As part of the transaction, Allscripts intends to continue to offer medication services to existing and future clients of Allscripts under a co-marketing agreement. Closing of the transaction
According to QuantRx, this new patent for oral testing devices expands the company’s protection, and will allow it to bring its ultrasensitive RapidSense technology to address the point-of-care
Chest-1 is a Phase III multi-center, double-blind, randomized, placebo-controlled trial in patients with inoperable chronic thromboembolic pulmonary hypertension. The trial will involve 270 patients who will be randomized
The company announced revenues of $17.2 million for the quarter ended December 31, 2008. This compares to revenues of $19.8 million for the quarter ended December 31, 2007.
The FDA approval is based on results from a multicenter study comparing catheter ablation to drug therapy for the treatment of atrial fibrillation (AFib). In this randomized clinical